Our findings of CCND1 and/or CDK4 allow us the suggestion that the selective CDK4/6 inhibitor Palbociclib (IBRANCE®, Pfizer Inc.)may be a promising treatment option in unresectable or metastasized tumor stages. Here, CDK4 is linked to neoplasm.